Botanix Pharmaceuticals Ltd Total Assets
Botanix Pharmaceuticals Ltd total assets. Based on the latest financial reports, Botanix Pharmaceuticals Ltd (BOT) holds total assets worth AU$129.10 Million AUD (≈ $91.34 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BOT company net worth for the company's overall valuation and market capitalisation.
Total Assets of Botanix Pharmaceuticals Ltd (1989–2025)
Total assets of Botanix Pharmaceuticals Ltd from 1989 to 2025. This chart illustrates how Botanix Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. See BOT live share price for real-time trading data and today's change.
Botanix Pharmaceuticals Ltd - Asset Composition Analysis
Botanix Pharmaceuticals Ltd Total Assets Breakdown (June 2025)
Botanix Pharmaceuticals Ltd total assets breakdown as of June 2025. Botanix Pharmaceuticals Ltd's total assets of AU$129.10 Million consist of 77.1% current assets and 22.9% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 50.3% |
| Accounts Receivable | AU$2.85 Million | 2.2% |
| Inventory | AU$28.08 Million | 21.8% |
| Property, Plant & Equipment | AU$1.38 Million | 1.1% |
| Intangible Assets | AU$28.12 Million | 21.8% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (1989–2025)
This chart illustrates how Botanix Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Botanix Pharmaceuticals Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Botanix Pharmaceuticals Ltd's current assets represent 77.1% of total assets in 2025, an increase from 39.8% in 1989.
- Cash Position: Cash and equivalents constituted 50.3% of total assets in 2025, up from 1.7% in 1989.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 8.0% in 1989.
- Asset Diversification: The largest asset category is intangible assets at 21.8% of total assets.
Botanix Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Botanix Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Botanix Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.00 | 22.21 | 17.98 |
| Quick Ratio | 2.87 | 21.89 | 17.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$74.67 Million | AU$79.17 Million | AU$23.40 Million |
Botanix Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Botanix Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.79 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 14.8% |
| Total Assets | AU$129.10 Million |
| Market Capitalization | $12.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Botanix Pharmaceuticals Ltd's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Botanix Pharmaceuticals Ltd's assets grew by 14.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Botanix Pharmaceuticals Ltd (1989–2025)
The table below shows the annual total assets of Botanix Pharmaceuticals Ltd from 1989 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$129.10 Million ≈ $91.34 Million |
+14.79% |
| 2024-06-30 | AU$112.46 Million ≈ $79.58 Million |
+352.83% |
| 2023-06-30 | AU$24.84 Million ≈ $17.57 Million |
+76.93% |
| 2022-06-30 | AU$14.04 Million ≈ $9.93 Million |
-36.05% |
| 2021-06-30 | AU$21.95 Million ≈ $15.53 Million |
-13.28% |
| 2020-06-30 | AU$25.31 Million ≈ $17.91 Million |
+386.76% |
| 2019-06-30 | AU$5.20 Million ≈ $3.68 Million |
-70.64% |
| 2018-06-30 | AU$17.71 Million ≈ $12.53 Million |
+199.80% |
| 2017-06-30 | AU$5.91 Million ≈ $4.18 Million |
+59.80% |
| 2016-06-30 | AU$3.70 Million ≈ $2.62 Million |
+179.94% |
| 2015-06-30 | AU$1.32 Million ≈ $934.38K |
-48.28% |
| 2014-06-30 | AU$2.55 Million ≈ $1.81 Million |
+31198.96% |
| 2013-06-30 | AU$8.16K ≈ $5.77K |
-54.31% |
| 2012-06-30 | AU$17.86K ≈ $12.63K |
-58.03% |
| 2011-06-30 | AU$42.55K ≈ $30.11K |
-27.38% |
| 2010-06-30 | AU$58.59K ≈ $41.46K |
-97.09% |
| 2009-06-30 | AU$2.02 Million ≈ $1.43 Million |
-14.83% |
| 2008-06-30 | AU$2.37 Million ≈ $1.68 Million |
-32.35% |
| 2007-06-30 | AU$3.50 Million ≈ $2.48 Million |
+39.57% |
| 2006-06-30 | AU$2.51 Million ≈ $1.77 Million |
-31.85% |
| 2005-06-30 | AU$3.68 Million ≈ $2.60 Million |
+51.68% |
| 2004-06-30 | AU$2.43 Million ≈ $1.72 Million |
-17.42% |
| 2003-06-30 | AU$2.94 Million ≈ $2.08 Million |
-34.79% |
| 2002-06-30 | AU$4.51 Million ≈ $3.19 Million |
-23.17% |
| 2001-06-30 | AU$5.86 Million ≈ $4.15 Million |
+11.31% |
| 2000-06-30 | AU$5.27 Million ≈ $3.73 Million |
-67.38% |
| 1999-06-30 | AU$16.15 Million ≈ $11.43 Million |
-46.81% |
| 1998-06-30 | AU$30.36 Million ≈ $21.48 Million |
-39.59% |
| 1997-06-30 | AU$50.26 Million ≈ $35.56 Million |
-11.89% |
| 1996-06-30 | AU$57.05 Million ≈ $40.36 Million |
-16.30% |
| 1995-06-30 | AU$68.16 Million ≈ $48.23 Million |
+40.34% |
| 1994-06-30 | AU$48.56 Million ≈ $34.36 Million |
+27.70% |
| 1993-06-30 | AU$38.03 Million ≈ $26.91 Million |
+46.72% |
| 1992-06-30 | AU$25.92 Million ≈ $18.34 Million |
-5.44% |
| 1991-06-30 | AU$27.41 Million ≈ $19.40 Million |
+7.15% |
| 1990-06-30 | AU$25.58 Million ≈ $18.10 Million |
+6.32% |
| 1989-06-30 | AU$24.06 Million ≈ $17.03 Million |
-- |
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more